- What led you to the creation of VEKTOR DIREKTOR?
Having worked in MVDA software and PAT for a significant proportion of my career as a user and developer I realised that there was a market opportunity for MVDA software that provided Enhanced Capabilities that existing software packages lacked and certain advanced features or capabilities that the VEKTOR DIREKTOR can offer such as drag n’drop functionality, highly interactive analysis routines and the easy integration with third-party systems. Developing our portfolio of software allows for the integration of cutting-edge algorithms for PAT and other industrial techniques.
Most importantly a User-Friendly Interface was designed, as many existing MVDA tools can be complex and difficult to use. VEKTOR DIREKTOR (and the related product ProaXesS) focus on providing a more intuitive and user-friendly interface, making it accessible to a broader audience to develop methods and models. KAX Group were also highly focused on Customization and Flexibility: so that our PAT users can tailor the analysis to their specific needs and preferences. The simple integration also allows for Process Improvements: the software through faster and more efficient data analysis allows end users to achieve their goals in a timely manner.
KAX Group software is also Hardware / Instrument Agnostic and are able to seamlessly integrate with almost all instruments and hardware that clients are already using, enhancing the overall workflow and productivity.
Addressing Specific Needs: Different industries and research fields have unique requirements. We are constantly developing enhancements to our software that allows for the creation of specialized tools that cater to these specific needs.
- Why do you think VEKTOR DIREKTOR & ProaXesS should be the MVDA software of choice for pharmaceutical process scientists and manufacturers?
For all the reasons above. Plus we are about to add a new software package, VEKTOR VAULT, that creates a secure overarching “container” for VEKTOR DIREKTOR and ProaXesS models and methods. This will enable both the raw data and all methods and models derived from the data to be approved and managed providing full CFR 21 Part 11 compliance as well as a simple way to access audit trail for QA/RA to access for both internal and external audits. This then enables pharma companies to easily export approved models to full GMP operations where required or if not store all methods and model versions to guarantee full end-to-end internal process management is retained at every step.
- If you had to pick one advantage of VEKTOR DIREKTOR what would it be and why?
VEKTOR DIREKTOR represents simplicity in MVDA software. The fact that it is so simple to get up and running and so intuitive to use means there is very little time required for set-up and training. There is no need to learn any scripting language that allowing PAT personnel to be up and running in a matter of hours. With the updates in Version 2.0 clients can now also access new preprocessing methods, advanced plotting routines, machine learning algorithms and improvements to classic routines making it even easier for new users and experienced users alike to generate results.
- When you see other software available on the market without pointing to a specific company what do you see as their major disadvantages?
One of the major disadvantages of other MVDA software on the market is the sales model. A lot of them require subscription licenses. KAX Group offers flexibility. We offer perpetual licenses with optional annual maintenance and support fee that also covers all upgrades automatically to the software. We also offer subscriptions to those who want to take that path and provide a server-based license system allowing easier deployment to a larger number of users in the organisation. In addition KAX Group are able to assist or work with our clients on specific major PAT projects that they may need resources for. We have worked with clients such as HORIBA Inc.a nd Aprecia Pharmaceuticals in this space and are currently working on a few other projects globally.
- Do you have any plans for further software launches in 2025?
The main launch in Q1 is VEKTOR VAULT which we plan on launching at IFPAC in Bethesda in early March. PAT professionals attending IFPAC from the world of Pharmaceutical R&D and Production will be able to see demos of VEKTOR VAULT at our Booth #516 throughout the conference. Anyone who is not attending and would like a demo or just a conversation about how this could help their business is welcome to connect with myself Joon or Rajani in order to get in the diary.
- What motivates you in this space after so long in the industry what keeps you passionate about MVDA?
The people we get to meet and work with is what keep me motivated. Our clients and business partners as well as the other companies that work in MVDA have interesting stories and journeys that we take part in as a technology partner. It’s a real thriving community of scientists, engineers and technologists that are expert in their fields. We are constantly seeking to generate products and services that ultimately benefit consumers globally. In particular, the pharmaceutical and food industries main objective is to get safe products into the hands of people that contribute to human health on a daily basis. KAX Group helps with this delivery through the provision of validated software with a full lifecycle model. Compared to scripts written in some languages that change with the wind, KAX Group products are stable, secure and are based on proven science.
